Prevail Gets $75M For Parkinson’s Gene Therapy, Bolstering NY Biotech – Xconomy
Endpoints News |
Prevail Gets $75M For Parkinson’s Gene Therapy, Bolstering NY Biotech
Xconomy A potential gene therapy for Parkinson’s disease has just gotten a big boost thanks to one of the larger Series A investment rounds in years for a New York biotech. The funding, for Prevail Therapeutics, provides another jolt for the city’s life … Prevail grabs $75MA round in the hunt for new gene therapies to stop the destruction caused by Parkinson’sEndpoints News Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with …Business Wire (press release) |
Life Sciences Intellectual Property Review |
EPO grants second CRISPR patent to ERS Genomics
Life Sciences Intellectual Property Review The European Patent Office (EPO) has granted a second CRISPR/Cas9 patent to a specialist genomics company, one month after revoking the Broad Institute of Harvard and MIT’s patent relating to the technology. ERS Genomics announced the EPO’s approval of … |